source
- Pfizer secures up to $1.5 billion from Blackstone to fund berobenatide obesity drug developmentPfizer announced a financing arrangement with Blackstone Life Sciences that could provide up to $1.5 billion to support the development of berobenatide, an obesity drug acquired from Metsera. The…
- FDA’s fast-track voucher program appears to be discontinued, report findsA recent report indicates that the FDA’s expedited voucher program, launched to speed approval of certain drugs, has not issued any new vouchers in the six months since former commissioner Marty Ma…